目前和未来的 HCV 挑战：来自意大利专家小组的见解。
Current and future challenges in HCV: insights from an Italian experts panel.
机构信息
Infectious Diseases, Polyclinic of Rome Tor Vergata, Rome, Italy.
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.
出版信息
Infection. 2018 Apr;46(2):147-163. doi: 10.1007/s15010-017-1093-1. Epub 2017 Nov 2.
BACKGROUND
The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages.
METHODS
A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens.
RESULTS AND CONCLUSIONS
Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.
背景
直接作用抗病毒药物（DAAs）的新近出现，由于极高的持续病毒学应答（SVR）率和极好的耐受性，允许在所有疾病阶段进行治疗，因此极大地改变了丙型肝炎病毒（HCV）的治疗方案。
方法
一组意大利专家于 2016 年 11 月和 2017 年 1 月两次开会，就一些未解决的问题提供进一步的支持，并根据即将推出的方案为个性化 HCV 护理提供指导。
结果和结论
由于不断积累新的数据，国际和国家肝脏学会发布的治疗建议旨在指导临床医生管理 HCV 感染，这些建议因各种原因可能不适用于所有医疗保健环境。此外，一些差距仍然存在，需要治疗的患者群体也在不断发展。
Zotero 插件